Stockscreener 앱 받기
3.90
3.23%
-0.13
시간 외 거래:
3.94
0.04
+1.03%
전일 마감가:
$4.03
열려 있는:
$4
하루 거래량:
1.19M
Relative Volume:
1.01
시가총액:
$322.42M
수익:
-
순이익/손실:
$-297.11M
주가수익비율:
-0.7514
EPS:
-5.19
순현금흐름:
$-216.95M
1주 성능:
-15.77%
1개월 성능:
-37.40%
6개월 성능:
-74.87%
1년 성능:
-56.52%
1일 변동 폭
$3.87
$4.155
1주일 범위
$3.87
$5.09
52주 변동 폭
$3.81
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
3.90 | 322.42M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 개시 | Stifel | Buy |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Alliancebernstein L.P. Has $370,000 Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
The Goldman Sachs Group Cuts Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $10.00 - Defense World
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge - simplywall.st
Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years ago - Yahoo Finance
Phathom Pharmaceuticals appoints Ted Schroeder to board By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals appoints new board member By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals appoints new board member - Investing.com
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of D - GuruFocus
Phathom Pharmaceuticals Appoints Theodore Schroeder to Board - TipRanks
Phathom Pharmaceuticals Appoints Ted Schroeder To Its Board Of Directors - marketscreener.com
Phathom Pharmaceuticals appoints Ted Schroeder to board - Investing.com
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors - GlobeNewswire
Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan
Vanguard Group Inc. Increases Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Wellington Management Group LLP Reduces Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals’ (PHAT) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
9,100 Shares in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Acquired by KLP Kapitalforvaltning AS - Defense World
Phathom Pharmaceuticals stock hits 52-week low at $4.07 By Investing.com - Investing.com Canada
Phathom Pharmaceuticals stock hits 52-week low at $4.07 - Investing.com
Phathom Pharmaceuticals CFO Molly Henderson sells $16,739 in stock By Investing.com - Investing.com Canada
Phathom Pharmaceuticals CFO Molly Henderson sells $16,739 in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - Yahoo Finance
Commonwealth Equity Services LLC Acquires 40,362 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - simplywall.st
Analysts Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) PT at $22.17 - Defense World
Guggenheim Reiterates “Buy” Rating for Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
Needham & Company LLC Reaffirms Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade) (PHAT) - Seeking Alpha
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
GI Disease Leader Phathom Takes Center Stage at Major Healthcare Conference - Stock Titan
Craig-Hallum Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT) - The Globe and Mail
Needham Remains a Buy on Phathom Pharmaceuticals (PHAT) - The Globe and Mail
Critical Analysis: Quoin Pharmaceuticals (NASDAQ:QNRX) & Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World
When (PHAT) Moves Investors should Listen - news.stocktradersdaily.com
Change at the top for Phathom as Basta replaces Curran - biocentury.com
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom's New CEO Stakes Future on Stock Price and Revenue Goals - Stock Titan
Phathom Pharmaceuticals Announces Leadership Transition in 2025 - TipRanks
Phathom Pharmaceuticals Names Steven Basta CEO - MarketScreener
Phathom Pharmaceuticals Announces Leadership Succession - MarketScreener
Phathom Pharmaceuticals appoints new CEO - Investing.com
Kenan Thompson partners with Phathom for GERD treatment By Investing.com - Investing.com Philippines
Kenan Thompson partners with Phathom for GERD treatment - Investing.com India
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan) - The Manila Times
Actor and Comedian Kenan Thompson Teams Up with Phathom - GlobeNewswire
SNL Legend Kenan Thompson Reveals Personal GERD Battle, Champions New Breakthrough Treatment - Stock Titan
Virtu Financial LLC Acquires New Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Raymond James Financial Inc. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Charles Schwab Investment Management Inc. Has $2.87 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Bank of New York Mellon Corp Purchases 4,557 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):